NCT00002183View on ClinicalTrials.gov

A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Abacavir sulfate

DRUG

Amprenavir

DRUG

Lamivudine

DRUG

Zidovudine

Trial Locations (3)

30308

AIDS Research Consortium of Atlanta, Atlanta

80262

Univ of Colorado Health Sciences Ctr, Denver

92103

UCSD, San Diego

Sponsors

Lead Sponsor

Glaxo Wellcome
All Listed Sponsors
lead

Glaxo Wellcome

INDUSTRY

NCT00002183 - A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection | Biotech Hunter | Biotech Hunter